Distressed PE Funds Focused on Biotech - Recommendations?

A friend has a company with very strong patents. They were challenged by a competitor and the competitor lost. The tech itself has good applications, and a clear path to approvals, plus it made it through initial trials. 

The company was publicly traded and ran into some issues with the SEC, and so, it's distressed.

Anyone have recommendations on who they should talk to? I'm thinking this would be a good size for a firm that can deploy ~$30m - $50m.

Friend is very reasonable and good to work with, he just doesn't want to see the tech wasted.

13 Comments
 

I know a special sits team that could be interested and writes checks in the range you mentioned. But what exactly does your friend want to do/what's his goal? 

Do you know if he's only open to cash or would he accept scrip? 

What's the existing structure of the company today - any real assets to speak of or just the IP and a ticker? 

Is he looking for someone to takeover and basically turnaround/bootstrap the company through trials and hopefully approval or is he open to IP sales/leasing to qualified strategics that would want to do something with it? 

Don't need answers to these here just wanted to show there's interest and if the feeling's mutual, feel free to PM me. 

"If you don't have any enemies in life you have never stood up for anything" - Winston Churchill | "It's a testament to the sheer belligerence of the profession that people would rather argue about the 'risk-adjusted returns' of using inferior tooth cleaning methods." - kellycriterion
 

PrivateTechquity 🚀GME🚀

I know a special sits team that could be interested and writes checks in the range you mentioned. But what exactly does your friend want to do/what's his goal? 

Do you know if he's only open to cash or would he accept scrip? 

What's the existing structure of the company today - any real assets to speak of or just the IP and a ticker? 

Is he looking for someone to takeover and basically turnaround/bootstrap the company through trials and hopefully approval or is he open to IP sales/leasing to qualified strategics that would want to do something with it? 

Don't need answers to these here just wanted to show there's interest and if the feeling's mutual, feel free to PM me. 

Old thread sir!

 

@m_1 your comment got automodded away

"If you don't have any enemies in life you have never stood up for anything" - Winston Churchill | "It's a testament to the sheer belligerence of the profession that people would rather argue about the 'risk-adjusted returns' of using inferior tooth cleaning methods." - kellycriterion
 

Voluptatem sed dolorem ea iure autem quia architecto cupiditate. Sit suscipit eaque dolorem qui minus praesentium fugiat. Veniam sapiente ex perspiciatis velit molestias totam et ratione. At possimus quo dolor facere omnis quasi. Ut explicabo et magni sapiente dolor quidem. Modi amet saepe laboriosam voluptatibus omnis explicabo nostrum.

In consequuntur debitis non. Sunt quaerat eum eius neque doloribus soluta. Vero sunt est ducimus minima non omnis culpa. Eaque placeat illo eius odio fugit iusto.

"If you don't have any enemies in life you have never stood up for anything" - Winston Churchill | "It's a testament to the sheer belligerence of the profession that people would rather argue about the 'risk-adjusted returns' of using inferior tooth cleaning methods." - kellycriterion

Career Advancement Opportunities

November 2026 Private Equity

  • Blackstone Group 99.6%
  • The Riverside Company 99.3%
  • KKR (Kohlberg Kravis Roberts) 98.9%
  • Warburg Pincus 98.5%
  • Vista Equity Partners 98.2%

Overall Employee Satisfaction

November 2026 Private Equity

  • Blackstone Group 99.6%
  • KKR (Kohlberg Kravis Roberts) 99.3%
  • The Riverside Company 98.9%
  • Ardian 98.5%
  • Warburg Pincus 98.1%

Professional Growth Opportunities

November 2026 Private Equity

  • Bain Capital 99.6%
  • Blackstone Group 99.3%
  • The Riverside Company 98.9%
  • Starwood Capital Group 98.5%
  • KKR (Kohlberg Kravis Roberts) 98.2%

Total Avg Compensation

November 2026 Private Equity

  • Principal (9) $653
  • Director/MD (24) $547
  • Vice President (100) $364
  • 3rd+ Year Associate (106) $280
  • 2nd Year Associate (236) $272
  • 1st Year Associate (414) $231
  • 3rd+ Year Analyst (33) $157
  • 2nd Year Analyst (97) $134
  • 1st Year Analyst (274) $126
  • Intern/Summer Associate (40) $79
  • Intern/Summer Analyst (357) $61
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
dosk17's picture
dosk17
98.9
7
GameTheory's picture
GameTheory
98.9
8
DrApeman's picture
DrApeman
98.9
9
CompBanker's picture
CompBanker
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”